Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
NCT00582790 · University of Wisconsin, Madison · PHASE2 · terminated · last registry update 2019-11-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “slow accrual” | – | Registry record, University of Wisconsin, Madison |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL2RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-11-17Also stopped (terminated): The University of Texas Medical Branch, Galveston, a drug against IL2RA (NCT01387659)
- 2020-10-30Also stopped (terminated): M.D. Anderson Cancer Center, Adoptive Immunotherapy + Aldesleukin (NCT02757391)
- 2020-10-29Results posted on the registry: University of Chicago, 4-peptide melanoma vaccine + Ontak (NCT00515528)
- 2020-09-24Also stopped (terminated): M.D. Anderson Cancer Center, Fludarabine + Cyclophosphamide (NCT00698009)
- 2020-09-24Also stopped (terminated): M.D. Anderson Cancer Center, Temozolomide + Velban (NCT00505635)
- 2020-07-24Also stopped (withdrawn): Jonsson Comprehensive Cancer Center, Aldesleukin + Cellular Therapy (NCT03506802)
- 2020-07-22Also stopped (terminated): Celularity Incorporated, PNK-007 + Cyclophosphamide (NCT02781467)
- 2020-04-27Results posted on the registry: University of California, San Francisco, Gemcitabine + Navelbine (NCT00632827)
- 2020-04-27Also stopped (terminated): University of California, San Francisco, Gemcitabine + Navelbine (NCT00632827)
- 2020-04-01Results posted on the registry: H. Lee Moffitt Cancer Center and Research Institute, Pembrolizumab + Interleukin-2 (NCT02964078)
- 2020-03-18Results posted on the registry: Eisai Inc., Denileukin diftitox + Cyclophosphamide (NCT00211185)
- 2020-02-28Phase 3 first posted: ElsaLys Biotech, Inolimomab (Leukotac) (NCT04289103)
- 2020-02-26Results posted on the registry: ADC Therapeutics S.A., ADCT-301 (NCT02588092)
- 2020-02-26Also stopped (terminated): ADC Therapeutics S.A., ADCT-301 (NCT02588092)
- 2020-02-19Results posted on the registry: M.D. Anderson Cancer Center, HDIL-2 + recMAGE-A3 + AS15 (NCT01266603)
- 2020-02-11Results posted on the registry: University of British Columbia, Tacrolimus + Tacrolimus (NCT01265537)
- 2020-01-30Results posted on the registry: Adienne SA, Begelomab + Conventional Second-line Treatment (NCT02411084)
- 2020-01-30Also stopped (terminated): Adienne SA, Begelomab + Conventional Second-line Treatment (NCT02411084)
- 2020-01-22Results posted on the registry: Inge Marie Svane, Cyclophosphamide + Fludarabine (NCT02379195)
- 2020-01-02Also stopped (withdrawn): Roswell Park Cancer Institute, Cyclophosphamide + Fludarabine (NCT03935347)
- 2019-12-16Also stopped (withdrawn): National Cancer Institute (NCI), Aldesleukin + Fludarabine (NCT02390739)
- 2019-12-10Also stopped (terminated): National Cancer Institute (NCI), Cyclophosphamide + Fludarabine (NCT01369875)
- 2019-12-10Also stopped (terminated): National Cancer Institute (NCI), Anti-VEGFR2 CAR CD8 plus PBL + Cyclophosphamide (NCT01218867)
- 2019-11-21Also stopped (terminated): National Cancer Institute (NCI), Vemurafenib + Young TIL (NCT01585415)
- 2019-11-19Also stopped (terminated): National Cancer Institute (NCI), Anti-NY ESO-1 T-cell receptor PBL + aldesleukin (NCT00670748)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision